Evidence map›Paper›PMID 27018820›Full record

ArticleEpidemiology and infection2016

The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay.

P A C Maple, J Haedicke, M Quinlivan, S P Steinberg, A A Gershon, K E Brown, J Breuer

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Epidemiology and infection, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

P A C MapleVirus Reference Department,Public Health England,Reference Microbiology Services,Colindale,London,UK.ORCID http://orcid.org/0000-0002-5534-5191
J HaedickeDepartment of Infection,The Cruciform Building,University College London,London,UK.
M QuinlivanDepartment of Infection,The Cruciform Building,University College London,London,UK.
S P SteinbergDepartment of Pediatrics,Columbia University College of Physicians and Surgeons,New York,USA.
A A GershonDepartment of Pediatrics,Columbia University College of Physicians and Surgeons,New York,USA.
K E BrownVirus Reference Department,Public Health England,Reference Microbiology Services,Colindale,London,UK.
J BreuerDepartment of Infection,The Cruciform Building,University College London,London,UK.
University College London · GBColumbia College · CAPublic Health England · GB

Funding

VZV in the enteric nervous system: pathogenesis and consequencesR01DK093094 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MICHAEL D GERSHON, Anne A. Gershon · 2011 to 2026
$5.9M
Medical Research Council G0700814NIDDK NIH HHS R01 DK093094Wellcome Trust
6 · The paper itself

Abstract

Healthcare workers (HCWs) reporting no history of varicella frequently receive varicella vaccination (vOka) if they test varicella-zoster virus (VZV) immunoglobulin G (IgG) negative. In this study, the utilities of VZV-IgG time-resolved fluorescence immunoassay (VZV-TRFIA) and a commercial VZV-IgG purified glycoprotein enzyme immunoassay (gpEIA) currently used in England for confirming VZV immunity have been compared to the fluorescent-antibody-to-membrane-antigen assay (FAMA). A total of 110 HCWs received two doses of vOka vaccine spaced 6 weeks apart and sera collected pre-vaccination (n = 100), at 6 weeks post-completion of vaccination (n = 86) and at 12-18 months follow-up (n = 73) were analysed. Pre-vaccination, by FAMA, 61·0% sera were VZV IgG negative, and compared to FAMA the sensitivities of VZV-TRFIA and gpEIA were 74·4% [95% confidence interval (CI) 57·9-87·0] and 46·2% (95% CI 30·1-62·8), respectively. Post-completion of vaccination the seroconversion rate by FAMA was 93·7% compared to rates of 95·8% and 70·8% determined by VZV-TRFIA and gpEIA, respectively. At 12-18 months follow-up seropositivity rates by FAMA, VZV-TRFIA and gpEIA were 78·1%, 74·0% and 47·9%, respectively. Compared to FAMA the sensitivities of VZV-TRFIA and gpEIA for measuring VZV IgG following vaccination were 96·4% (95% CI 91·7-98·8) and 74·6% (95% CI 66·5-81·6), respectively. Using both FAMA and VZV-TRFIA to identify healthy adult VZV susceptibles and measure seroconversion showed that vOka vaccination of HCWs is highly immunogenic.

Indexed as

Fluorescent Antibody TechniqueFluoroimmunoassayImmunoenzyme TechniquesAdultAntibodies, ViralChickenpox VaccineHealth PersonnelHerpesvirus 3, HumanHumansImmunoglobulin GMiddle AgedYoung AdultAntibodies, ViralChickenpox VaccineImmunoglobulin GFluorescent-antibody-to-membrane-antigen-assayhealthcare workersvOka vaccineVZV glycoprotein EIAVZV immunoglobulin GVZV time-resolved fluorescence immunoassay

Identifiers

PMID27018820
PMCPMC5726866
OpenAlexW2318027784

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.